Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DCAT Week
Not Confirmed
Contact SupplierDCAT Week
Industry Trade Show
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
19 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/19/3208493/0/en/Historic-U-S-Cannabis-Rescheduling-Unlocks-Potential-Growth-Opportunities-for-MediPharm-Labs-Backed-by-the-Company-s-Suite-of-Licenses-and-Proven-U-S-Clinical-Trial-Supply-Experien.html
10 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3203589/0/en/MediPharm-Labs-Announces-Board-of-Directors-Changes-Shelley-Potts-Steps-Down-Michael-Bumby-Returns.html
04 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/04/3199808/0/en/MediPharm-Labs-Completes-First-Shipment-to-France.html
14 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/14/3188418/0/en/MediPharm-Announces-Complete-Dismissal-of-Defamation-Action-Initiated-by-Apollo-Nobul-and-Regan-McGee-Under-Ontario-Anti-SLAPP-Law.html
13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187262/0/en/MediPharm-Advances-Global-Reach-in-Q3-2025-with-Double-Digit-Revenue-Growth-and-Strong-International-Medical-Cannabis-Gains.html
10 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/10/3185138/0/en/MediPharm-Labs-Sets-Date-to-Report-Third-Quarter-2025-Financial-Results.html
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2022-08-24
Pay. Date : 2022-02-09
DMF Number : 36490
Submission : 2022-02-18
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]LISTED APIs
About the Company : MediPharm Labs is a full-service pharmaceutical company that specializes in producing and manufacturing high-quality, purified cannabinoid-based derivatives and pharmaceutical ingredients. It of...
About the Company : MediPharm Labs is a full-service pharmaceutical company that specializes in producing and manufacturing high-quality, purified cannabinoid-based derivatives and pharmaceutical ingredients. It of...
About the Company : MediPharm Labs is a full-service pharmaceutical company that specializes in producing and manufacturing high-quality, purified cannabinoid-based derivatives and pharmaceutical ingredients. It of...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Tetrahydrocannabinol,Inapplicable
Therapeutic Area: Neurology Brand Name: Pink Kush
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2023
Lead Product(s) : Tetrahydrocannabinol,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Pink Kush
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 27, 2023
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2023
Details:
Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.
Lead Product(s): Cannabidiol,Inapplicable
Therapeutic Area: Neurology Brand Name: RHO Phyto
Study Phase: Approved FDFProduct Type: Controlled Substance
Recipient: Avicanna
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2023
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Avicanna
Deal Size : Undisclosed
Deal Type : Agreement
Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary ...
Details : Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.
Product Name : RHO Phyto
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 26, 2023
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Cannabidiol,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2023
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 01, 2023
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 01, 2023
Details:
MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: National Institutes of Health
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
Details : MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients dia...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 09, 2022
Details:
New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Lead Product(s): Cannabigerol,Cannabidiol
Therapeutic Area: Neurology Brand Name: CBG/CBD
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2022
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Product Name : CBG/CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 05, 2022
Details:
Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Lead Product(s): Cannabinoid,Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2022
Lead Product(s) : Cannabinoid,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 05, 2022
Details:
McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.
Lead Product(s): Cannabidiol,Inapplicable
Therapeutic Area: Sleep Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: McMaster University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2021
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-con...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2021
Details:
Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Sleep Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: McMaster University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
MediPharm Labs is a supplier offers 4 products (APIs, Excipients or Intermediates).
Find a price of Cannabidiol bulk with DMF offered by MediPharm Labs
Find a price of Cannabigerol bulk offered by MediPharm Labs
Find a price of Cannabinol bulk offered by MediPharm Labs
Find a price of Tetrahydrocannabinol bulk offered by MediPharm Labs
Share 
